소아 기능성 변비의 치료에 영향을 미치는 인자
Factors Contributing to Treatment Outcome of Functional Constipation in Children
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to evaluate the clinical features and factors contributing to treatment outcome for chronic functional constipation in children. Methods: We analyzed the medical records of patients with constipation, who visited the inpatient or outpatient clinic of the Department of Pediatrics of Pusan National University Hospital, between January 1998 and December 2007. The clinical features, outcomes, and factors affecting the treatment response according to the main drug (lactulose vs. PEG 4000) were analyzed retrospectively. Results: Two hundred forty children (142 males and 98 females) were enrolled in this study. The mean age was 51.2±37.9 months. The duration of symptoms was 32.6±33.7 months. The accompanying symptoms were as follows: encopresis, 91 (30.4%); abdominal pain, 76 (31.6%); and blood-tinged stool, 37 (15.4%). The treatment response was achieved earlier in females (p＜0.001), patients with accompanying symptoms (p＜0.05), and patients treated with PEG 4000 (p=0.001). The duration of symptoms (p＜0.05) and stool frequency before treatment (p＜0.05) were related to a delayed treatment response. Relapse occurred in 7 children, all of whom were treated successfully later. Conclusion: Factors contributing to treatment response are female gender, accompanying symptoms, duration of symptoms, and stool frequency before treatment. PEG 4000 is superior to lactulose in response time and taken into consideration as a primary drug for the treatment of functional constipation of children. Early treatment and sufficient treatment time may also be important factors to achieve an early response and prevent relapse. (Korean J Pediatr Gastroenterol Nutr 2010; 13: 36∼43)
Abstract
Purpose: The aim of this study was to evaluate the clinical features and factors contributing to treatment outcome for chronic functional constipation in children. Methods: We analyzed the medical records of patients with constipation, who visited the inpatient or outpatient clinic of the Department of Pediatrics of Pusan National University Hospital, between January 1998 and December 2007. The clinical features, outcomes, and factors affecting the treatment response according to the main drug (lactulose vs. PEG 4000) were analyzed retrospectively. Results: Two hundred forty children (142 males and 98 females) were enrolled in this study. The mean age was 51.2±37.9 months. The duration of symptoms was 32.6±33.7 months. The accompanying symptoms were as follows: encopresis, 91 (30.4%); abdominal pain, 76 (31.6%); and blood-tinged stool, 37 (15.4%). The treatment response was achieved earlier in females (p＜0.001), patients with accompanying symptoms (p＜0.05), and patients treated with PEG 4000 (p=0.001). The duration of symptoms (p＜0.05) and stool frequency before treatment (p＜0.05) were related to a delayed treatment response. Relapse occurred in 7 children, all of whom were treated successfully later. Conclusion: Factors contributing to treatment response are female gender, accompanying symptoms, duration of symptoms, and stool frequency before treatment. PEG 4000 is superior to lactulose in response time and taken into consideration as a primary drug for the treatment of functional constipation of children. Early treatment and sufficient treatment time may also be important factors to achieve an early response and prevent relapse. (Korean J Pediatr Gastroenterol Nutr 2010; 13: 36∼43)
참고문헌 (23)
- Loening-Baucke V, "Prevalence, symptoms and outcome of constipation in infants and toddlers", J Pediatr, 146, pp.359~363 (2005)
- Loening-Baucke V, "Prevalence rates for constipation and faecal and urinary incontinence", Arch Dis Child, 92, pp.486~489 (2007)
- Baker SS, "Constipation in infants and children: evaluation and treatment. A medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition", J Pediatr Gastroenterol Nutr, 29, pp.612~626 (1999)
- Borowitz SM, "Precipitants of constipation during early childhood", J Am Board Fam Pract, 16, pp.213~218 (2003)
- Dupont C, "Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children", J Pediatr Gastroenterol Nutr, 41, pp.625~633 (2005)
- Loening-Baucke V, "Polyethylene glycol without electrolytes for children with constipation and encopresis", J Pediatr Gastroenterol Nutr, 34, pp.372~377 (2002)
- 이정희, "소아 만성 기능성변비 치료에서 전해질이 함유되지 않은Polyethylene glycol (PEG) 4000의 분변박힘 제거효과 및 안전성", Korean Journal of Pediatrics, 51(4), pp.391~395 (2008), 대한소아과학회
- 엄지현, "소아의 만성 기능성 변비 치료에 polyethylene clycol 4000과 락툴로스의 효과 비교", Korean Journal of Pediatrics, 50(8), pp.752~756 (2007), 대한소아과학회
- 안윤진, "소아 만성 기능성 변비의 치료 성적과 장기적 예후", 대한소아소화기영양학회지, 9(2), pp.200~209 (2006), 대한소아소화기영양학회
- Loening-Baucke V, "Factors responsible for persistence of childhood constipation", J Pediatr Gastroenterol Nutr, 6, pp.915~922 (1987)
- Kot TV, "Lactulose in the management of constipation: a current review", Ann Pharmacother, 26, pp.1277~1282 (1992)
- Wang BX, "Forlax in the treatment of childhood constipation: a randomized, controlled, multicenter clinical study", Zhongguo Dang Dai Er Ke Za Zhi, 9, pp.429~432 (2007)
- Thomson MA, "Polyethylene glycol 3350 plus electrolytes for chronic constipation in children: a double blind, placebo controlled, crossover study", Arch Dis Child, 92, pp.996~1000 (2007)
- Candy DC, "of faecal impaction with polyethylene glycol plus electrolytes (PGE＋E) followed by a double-blind comparison of PEG＋E versus lactulose as maintenance therapy", J Pediatr Gastroenterol Nutr, 43, pp.65~70 (2006)
- Voskuijl W, "PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomized, controlled, multicenter trial", Gut, 53, pp.1590~1594 (2004)
- Gremse DA, "Comparison of polyethylene glycol 3350 and lactulose for treatment of chronic constipation in children", Clin Pediatr (Phila), 41, pp.225~229 (2002)
- Loening-Baucke V, "A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence", Pediatrics, 118, pp.528~535 (2006)
- Abi-Hanna A, "Constipation and encopresis in childhood", Pediatr Rev, 19, pp.23~30 (1998)
- 서정완, "소아의 배변장애-기능성 변비와 유분증", 대한의사협회지, 44, pp.59~68 (2001)
- 김재영, "소아 변비의 이해와 치료의 실제", Korean Journal of Pediatrics, 48(4), pp.355~362 (2005), 대한소아과학회
- van Ginkel R, "Childhood constipation: longitudinal follow-up beyond puberty", Gastroenterology, 125, pp.357~363 (2003)
- Sutphen JL, "Long-term follow-up of medically treated childhood constipation", Clin Pediatr (Phila), 34, pp.576~580 (1995)
- Staiano A, "Long-term follow-up of children with chronic idiopathic constipation", Dig Dis Sci, 39, pp.561~564 (1994)